TG Therapeutics Inc (NASDAQ:TGTX) – Equities research analysts at Jefferies Group upped their FY2018 earnings per share estimates for TG Therapeutics in a report released on Tuesday. Jefferies Group analyst M. Andrews now anticipates that the biopharmaceutical company will post earnings per share of ($1.62) for the year, up from their prior estimate of ($1.78). Jefferies Group also issued estimates for TG Therapeutics’ FY2019 earnings at ($1.94) EPS.
Several other research analysts have also issued reports on TGTX. BidaskClub upgraded TG Therapeutics from a “sell” rating to a “hold” rating in a research report on Tuesday, January 30th. ValuEngine upgraded TG Therapeutics from a “sell” rating to a “hold” rating in a research report on Friday, February 2nd. B. Riley reiterated a “buy” rating and issued a $21.50 price target on shares of TG Therapeutics in a report on Wednesday, January 17th. HC Wainwright reiterated a “buy” rating and issued a $33.00 price target on shares of TG Therapeutics in a report on Monday, January 8th. Finally, Zacks Investment Research lowered TG Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, January 13th. One analyst has rated the stock with a sell rating, two have issued a hold rating and nine have issued a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and a consensus price target of $25.50.
In related news, CFO Sean A. Power sold 32,006 shares of the business’s stock in a transaction that occurred on Tuesday, January 2nd. The stock was sold at an average price of $8.50, for a total value of $272,051.00. Following the completion of the sale, the chief financial officer now owns 517,464 shares in the company, valued at $4,398,444. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 16.70% of the stock is currently owned by insiders.
Hedge funds and other institutional investors have recently made changes to their positions in the stock. CIBC World Markets Inc. purchased a new stake in shares of TG Therapeutics in the fourth quarter valued at approximately $250,000. Ameriprise Financial Inc. lifted its holdings in TG Therapeutics by 150.2% during the second quarter. Ameriprise Financial Inc. now owns 277,235 shares of the biopharmaceutical company’s stock worth $2,786,000 after buying an additional 166,434 shares during the period. State Street Corp lifted its holdings in TG Therapeutics by 274.4% during the second quarter. State Street Corp now owns 2,638,683 shares of the biopharmaceutical company’s stock worth $26,515,000 after buying an additional 1,933,896 shares during the period. Raymond James Financial Services Advisors Inc. lifted its holdings in TG Therapeutics by 65.0% during the third quarter. Raymond James Financial Services Advisors Inc. now owns 81,104 shares of the biopharmaceutical company’s stock worth $961,000 after buying an additional 31,958 shares during the period. Finally, Schwab Charles Investment Management Inc. lifted its holdings in TG Therapeutics by 176.8% during the third quarter. Schwab Charles Investment Management Inc. now owns 243,485 shares of the biopharmaceutical company’s stock worth $2,886,000 after buying an additional 155,535 shares during the period. Hedge funds and other institutional investors own 47.44% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: This piece was published by American Banking News and is the sole property of of American Banking News. If you are viewing this piece on another domain, it was illegally copied and reposted in violation of United States & international copyright law. The legal version of this piece can be accessed at https://www.americanbankingnews.com/2018/02/15/equities-analysts-set-expectations-for-tg-therapeutics-incs-fy2018-earnings-tgtx.html.
About TG Therapeutics
TG Therapeutics, Inc (TG) is a biopharmaceutical company focused on the acquisition, development and commercialization of treatments for B-cell malignancies and autoimmune diseases. As of December 31, 2016, the Company was developing two therapies targeting hematological malignancies. TG-1101 (ublituximab) is a glycoengineered monoclonal antibody that targets a specific epitope on the cluster of differentiation (CD20) antigen found on mature B-lymphocytes.
Receive News & Ratings for TG Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TG Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.